Update of CryoLife Litigation and Recent Developments January 15, 2010.
On January 11,
2010, Medafor moved to dismiss CryoLife's Second Amended
Complaint. The brief in support of its motion is
here.
CryoLife filed its Second Amended Complaint on
December 28, 2009, after the District Court granted in
part Medafor's motion to dismiss CryoLife's First
Amended Complaint against Medafor. The Court
directed CryoLife to recast its complaint as directed by
the Court. The Court's order is here.
Orthovita to Market Medafor's MPH® Hemostatic Technology Under the Name VITASURE™.
MINNEAPOLIS, April 27, 2008 - Medafor is pleased to announce that it has signed a non-exclusive agreement with Orthovita, Inc., Philadelphia, Penna., to distribute Medafor's patented MPH® polysaccharide hemostatic technology under the private label VITASURE™.
Under the agreement, Orthovita will have distribution rights in the United States and Europe for the orthopedic and spine markets.
"VITASURE is an easy to use, cost effective hemostat that can be used throughout the surgical procedure," said Antony Koblish, President and C.E.O. of Orthovita. "We believe VITASURE fits exceptionally well with our sales force's call pattern focus on spine and orthopedic surgeries and will complement the use of our VITOSS® Bone Graft Substitute product line, including our newly launched VITOSS Bioactive Foam Bone Graft Substitute product."
Gary Shope, C.E.O. of Medafor, Inc., said, "This agreement puts Medafor's MPH technology into the hands of a leader among biologic companies looking to complement its existing product offerings with a superior hemostatic product."
Medafor's patented MPH absorbable hemostatic agent is a plant-based microporous, polysaccharide, flowable powder that is instantly ready to use, requires no mixing, no addition of patient blood or other components and no special handling or storage conditions. Pre-clinical evaluations, clinical studies and surgical use have shown the hemostatic capabilities of MPH to be comparable to the current popular choice of surgical hemostatic materials while its unique formulation allows for rapid absorption. The hemostat is fully absorbable with studies substantiating no trace of the material at the wound site within 24 to 48 hours of application, and because it degrades rapidly, it does not promote infection.
Orthovita (NASDAQ:VITA) is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic techologies for the development and commercialization of synthetic, biologically active, tissue engineering products.
Medafor is a privately held Minnesota Corporation based in Minneapolis. Medafor was founded to commercialize its patented hemostatic technology. MPH is a microporous, polysaccharide hemostatic agent that is engineered to rapidly dehydrate blood and accelerate clotting. Medafor received FDA approval for surgical use in 2006 and has held a CE Mark approval since 2003. BACK.
